PetCaseFinder

Peer-reviewed veterinary case report

Dog with gastrin tumor treated with octreotide acetate

By Kim, Sangho et al.·Published in Journal of the American Animal Hospital Association·2015·Department of Veterinary Sciences, Japan·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Treatment of Gastrin-Secreting Tumor With Sustained-Release Octreotide Acetate in a Dog.

Species:
dog

Plain-English summary

An 8-year-old male Shiba Inu was brought to the vet with symptoms including loose stool, excessive thirst, blood in urine, vomiting, and not wanting to eat. After tests, the vet found a gastrin-secreting tumor in the dog's liver. The dog was treated with medications to reduce stomach acid and a special drug called octreotide acetate to lower the high gastrin levels. Initially, the treatment worked well, but over time, the dog's symptoms returned, and unfortunately, the dog was lost to follow-up after about 17 months.

People also search for: Shiba Inu vomiting treatment · dog liver tumor symptoms · octreotide acetate for dogs

Abstract

An 8 yr old, intact male Shiba Inu was presented with loose stool, polydipsia, hematuria, vomiting, and anorexia. On abdominal ultrasonography, numerous nodules were detected in the hepatic parenchyma distributed diffusely throughout all lobes. Excisional biopsy of one of the nodules was performed via exploratory laparotomy. A histopathological diagnosis of the lesion was carcinoid, and the tumor cells stained positive to chromogranin A and gastrin. The serum gastrin level of the dog was 45,613 pg/mL (reference range: 160-284). In addition to medical treatment with omeprazole(c) and famotidine(e), suppression of gastrin secretion was attempted with octreotide acetate. A test dose of octreotide acetate significantly decreased the serum gastrin level to approximately one third of the baseline in 2 hr and the effect lasted approximately for 6 hr. On day 21, treatment with sustained-release formulation of octreotide acetate(a) (5 mg intramuscular, q 4 wk) was initiated. The serum gastrin concentration gradually decreased over 32 days and then progressively increased in parallel with the progression of the hepatic nodules. The dog gradually developed recurrence of initial clinical signs, and was lost to follow-up on day 510.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26535461/